Bioventus (BVS) EPS (Weighted Average and Diluted) (2021 - 2026)

Bioventus has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at $0.04 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 200.0% year-over-year to $0.04; the trailing twelve-month figure through Mar 2026 stood at $0.41 (up 178.85% YoY), and the FY2025 full-year result was $0.33, up 158.93% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at $0.04, down from $0.21 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $0.86 in Q4 2023, with the low at -$2.24 in Q2 2023.
• Historically, EPS (Weighted Average and Diluted) has averaged -$0.27 across 5 years, with a median of -$0.08 in 2024.
• Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) tumbled 201797.82% — and 2026, when it surged 200.0%.
• Bioventus' EPS (Weighted Average and Diluted) stood at -$1.11 in 2022, then soared by 177.48% to $0.86 in 2023, then sank by 109.3% to -$0.08 in 2024, then jumped by 362.5% to $0.21 in 2025, then sank by 80.95% to $0.04 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.04 (Q1 2026), $0.21 (Q4 2025), and $0.05 (Q3 2025), per Business Quant data.